Search

everythinglearnresearchcommunity

for

Search:↓

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Adding a second method to PROTACs could improve cancer treatment.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Mononuclear cells may protect against certain chemotherapy-induced hair loss.

Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.

New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.

Certain genetic variants in keratins increase the risk of tooth decay.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Janus kinase inhibitors show promise in treating autoimmune skin diseases.

Some people have a genetic variation that makes them less effective at breaking down drugs.

Inhibiting the PI3K/Akt pathway may help prevent radiation-induced liver injury.

T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.

JAK inhibitors are effective treatments for alopecia areata.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.

Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.

JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.